Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SDA +4.5%, MODV +1.6% (guidance)
Other news:
- NCNA +190.1% (Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024)
- ZNTL +38% (confirms the FDA has lifted the partial clinical hold on studies of azenosertib)
- NUVL +16.9% (Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines; commences public offering of $350.0 million of its shares of Class A common stock)
- ASND +16.2% (topline data from the pivotal double-blind placebo-controlled ApproaCH Trial of TransCon CNP)
- ADAG +13.8% (presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody ADG126)
- EVAX +12% (positive one-year data from the ongoing phase 2 trial with its lead asset EVX-01, an AI-designed personalized cancer vaccine)
- EXAS +9.8% (Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024)
- PDSB +7.3% (Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024)
- CGEM +7% (Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024)
- SSYS +6% (authorizes $50 million share repurchase program)
- CACI +5% (will announce during a conference call this morning, Sept. 16, at 8:30 a.m. Eastern time, that it has entered into a definitive agreement to acquire a company)
- STRO +4.7% (Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024)
- ACRV +4.6% (Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis)
- SMMT +2.9% (reports promising anti-tumor activity and safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024)
- CKPT +2.2% (announces cosibelimab longer-term results in advanced cutaneous squamous cell carcinoma presented at ESMO Congress 2024)
- MASI +1.9% (issues statement following Court's Order Holding Politan and Quentin Koffey in Contempt)
- DJT +1.7% (indicated higher following second assassination attempt on former President Donald Trump on Sunday)
- VSAT +1.6% (bought 55000 shares at $14.75-15.00 worth ~$820K)
- VYGR +1.6% (announces that the joint steering committee with its collaborator Neurocrine Biosciences (NBIX) has selected a development candidate in a gene therapy program for the potential treatment of an undisclosed neurological disease)
- AZN +1.5% (reports Imfinzi plus Imjudo demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial; reports IMFINZI (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial)
- AA +1.4% (agrees to sell its 25.1% stake in Ma'aden Joint Venture to Ma'aden)
- NVS +1.1% (reports Kisqali shows deepening benefit in new analysis)
- JAZZ +1.1% (Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024)
- HOLX +1% (announces $1.5 bln share repurchase authorization)
- NVCT +1% (Nuvectis Pharma with Summit Therapeutics threatening to dethrone Merck's Keytruda, Nuvectis' NXP900 is one to watch)